{"id":"nafamostat-mesilate","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL1091841","moleculeType":"Small molecule","molecularWeight":"443.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nafamostat inhibits serine proteases including thrombin, factor Xa, and kallikrein, thereby suppressing the intrinsic coagulation cascade and contact system activation. It is used primarily as an anticoagulant during hemodialysis and extracorporeal circulation procedures, and has been investigated for its anti-inflammatory and antiviral properties in conditions such as acute pancreatitis and severe respiratory infections.","oneSentence":"Nafamostat mesilate is a serine protease inhibitor that blocks multiple coagulation and inflammatory proteases to prevent thrombosis and inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:56:26.891Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anticoagulation during hemodialysis and extracorporeal circulation"},{"name":"Acute pancreatitis"},{"name":"Severe COVID-19 (investigational)"}]},"trialDetails":[{"nctId":"NCT07469072","phase":"PHASE2","title":"Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU)","status":"NOT_YET_RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2026-02-25","conditions":"Continuous Renal Replacement Therapy (CRRT)","enrollment":92},{"nctId":"NCT06500793","phase":"PHASE1","title":"Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)","status":"RECRUITING","sponsor":"Ensysce Biosciences","startDate":"2024-11-24","conditions":"Pharmacokinetics","enrollment":30},{"nctId":"NCT06150742","phase":"NA","title":"Nafamostat Efficacy in Phase 3 Registrational CRRT Study","status":"RECRUITING","sponsor":"Talphera, Inc","startDate":"2024-08-15","conditions":"Acute Kidney Injury","enrollment":70},{"nctId":"NCT06276010","phase":"NA","title":"Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO","status":"RECRUITING","sponsor":"Xiaotong Hou","startDate":"2024-07-01","conditions":"Extracorporeal Membrane Oxygenation Complication","enrollment":80},{"nctId":"NCT04473053","phase":"PHASE1, PHASE2","title":"DEFINE - Evaluating Therapies for COVID-19","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2020-07-03","conditions":"COVID-19","enrollment":71},{"nctId":"NCT06994312","phase":"NA","title":"The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration","status":"NOT_YET_RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2025-07-01","conditions":"Sepsis-induced Coagulopathy (SIC)","enrollment":282},{"nctId":"NCT06676085","phase":"NA","title":"A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation","status":"RECRUITING","sponsor":"Beijing Chao Yang Hospital","startDate":"2024-11-01","conditions":"ECMO","enrollment":60},{"nctId":"NCT04406415","phase":"PHASE1","title":"Oral Nafamostat in Healthy Volunteers (NAF-101)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2020-09-21","conditions":"Pharmacokinetics","enrollment":17},{"nctId":"NCT05090280","phase":"PHASE1","title":"Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2021-12-01","conditions":"Pharmacokinetics","enrollment":111},{"nctId":"NCT05874674","phase":"NA","title":"The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study","status":"RECRUITING","sponsor":"Wonju Severance Christian Hospital","startDate":"2023-12-01","conditions":"Dialysis; Complications, Bleeding","enrollment":100},{"nctId":"NCT04390594","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal","status":"TERMINATED","sponsor":"Institut Pasteur de Dakar","startDate":"2020-08-13","conditions":"COVID-19","enrollment":59},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT06375616","phase":"PHASE4","title":"Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI","status":"NOT_YET_RECRUITING","sponsor":"Shen Lei","startDate":"2024-04","conditions":"Sepsis","enrollment":156},{"nctId":"NCT04352400","phase":"PHASE2, PHASE3","title":"Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)","status":"UNKNOWN","sponsor":"University Hospital Padova","startDate":"2021-06-04","conditions":"COVID19","enrollment":256},{"nctId":"NCT06078839","phase":"PHASE4","title":"Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy","status":"NOT_YET_RECRUITING","sponsor":"Xu Li","startDate":"2023-10-01","conditions":"Sepsis, Sepsis-induced Coagulopathy, Nafamostat Mesilate","enrollment":778},{"nctId":"NCT05555641","phase":"PHASE2","title":"Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation","status":"UNKNOWN","sponsor":"Xiaobo Yang, MD","startDate":"2022-12-20","conditions":"Critical Illness, Anticoagulation","enrollment":40},{"nctId":"NCT05382078","phase":"","title":"Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-05-31","conditions":"Sepsis Syndrome, MODS, AKI","enrollment":188},{"nctId":"NCT04628143","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-12-21","conditions":"COVID-19","enrollment":13},{"nctId":"NCT04623021","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-09-25","conditions":"COVID-19","enrollment":104},{"nctId":"NCT04418128","phase":"PHASE2, PHASE3","title":"Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia","status":"UNKNOWN","sponsor":"Gyeongsang National University Hospital","startDate":"2020-06-10","conditions":"Corona Virus Infection, COVID-19","enrollment":84},{"nctId":"NCT02478242","phase":"PHASE4","title":"Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2010-07","conditions":"Acute Kidney Injury","enrollment":60},{"nctId":"NCT01486485","phase":"PHASE3","title":"Nafamostat Efficacy and Safety in Critically Ill Patients(NICE)","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2012-03","conditions":"Acute Kidney Injury","enrollment":160},{"nctId":"NCT01761994","phase":"PHASE4","title":"The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2007-09","conditions":"Acute Kidney Injury","enrollment":66},{"nctId":"NCT01001403","phase":"PHASE4","title":"Effect of Nafamostat on Postreperfusion Syndrome (PRS)","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2009-03","conditions":"Liver Transplantation, Postreperfusion Syndrome","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":449,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Futhan","no alternative name. Commercial brands are available.","CKD-314"],"phase":"marketed","status":"active","brandName":"Nafamostat Mesilate","genericName":"Nafamostat Mesilate","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nafamostat mesilate is a serine protease inhibitor that blocks multiple coagulation and inflammatory proteases to prevent thrombosis and reduce inflammation. Used for Anticoagulation during hemodialysis and extracorporeal circulation, Acute pancreatitis, Disseminated intravascular coagulation (DIC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}